Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Risk factor profiles associated with negative outcomes after use of tPA

Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year

Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions

IJERPH, Free Full-Text

Trends in acute ischemic stroke treatments and mortality in the United States from 2012 to 2018 in: Neurosurgical Focus Volume 51 Issue 1 (2021) Journals

Thrombolysis for acute ischaemic stroke: current status and future perspectives - The Lancet Neurology

Current Advances in Emergency Department Care of Acute Ischemic Stroke ( Stroke CME and Pharmacology CME) - Calculated Decisions - Emergency Department

Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era

The Neurotoxicity of Tissue Plasminogen Activator? - Jaspreet Kaur, Zonghang Zhao, Gary M. Klein, Eng H. Lo, Alastair M. Buchan, 2004

Frontiers Neuroprotection in Acute Ischemic Stroke: A Battle Against the Biology of Nature

Tenecteplase vs Alteplase in Acute Ischemic Stroke - REBEL EM - Emergency Medicine Blog

Outcomes of Treatment with Recombinant Tissue Plasminogen Activator in Patients Age 80 Years and Older Presenting with Acute Ischemic Stroke

Full article: Targeted nano-delivery strategies for facilitating thrombolysis treatment in ischemic stroke

Tissue Plasminogen Activator Market Size, Largest Share Market, Industry Report, 2018-2026, Bayer AG, Abcam, Merck & Company, Roche, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, and Cadila Healthcare Ltd.